Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
Date:8/11/2008

e in the clinical trials. In addition, we are very pleased to be working with leading clinical investigators at outstanding academic cancer research centers."

Merrimack has developed a broad intellectual property position around its oncology therapeutic portfolio, including MM121. This portfolio includes U.S. and international patent filings relating to compositions of matter and methods of use as well as licensed patents and pending patent applications, trade secrets and proprietary know-how.

About MM-121

MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. Upon initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development. Preclinical data exhibiting MM-121's impact on multiple cancer models (including lung, ovarian, breast, prostate and renal) were presented at the annual meeting of the American Association for Cancer Research in April 2008. The Phase 1 trial is being conducted at 3 centers in the United States.

About Merrimack

Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery, design and development of novel treatments for diseases in the areas of autoimmunity and cancer. Its autoimmune candidate, MM-093, is currently in Phase 2 clinical development. Its first oncology product, MM-121 is currently in Phase 1 clinical development. MM-093 and MM-121 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative therapeutics.
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... compound found in plants and food groups, notably red ... mitochondria, the cell,s energy supplier. "The results were ... at Harvard Medical School and the study,s senior author. ... The findings are to be published May ...
...  The Diagnostic Marketing Association ( DxMA ), serving marketing, ... device market segments, today presented its 2011 Marketer of ... ), a leading molecular diagnostics company. Presented at the ... recognizes innovation by marketers seeking to highlight their company ...
... SAN DIEGO, May 1, 2012 AnaptysBio, Inc., ... antibody discovery partnership with Gilead Sciences, Inc. to ... http://photos.prnewswire.com/prnh/20111205/SF16052LOGO ) Under this ... SHM-XEL platform will be transferred to Gilead for ...
Cached Biology Technology:More evidence for longevity pathway 2Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year 2AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences 2
(Date:4/17/2014)... COLUMBIA, Mo. April 17 In the most densely ... States, forests reflect two centuries of human needs, values ... logging and clearing forests for agriculture and development, have ... today, a U.S. Forest Service study reports. , The ... forest conditions and management needs in the Northern United ...
(Date:4/17/2014)... there was a word for chili peppers. Information about ... with a study of the appearance of words for ... where jalapeos were domesticated and highlight the value of ... Kraft et al.) of nine papers presented in a ... National Academy of Sciences on plant and animal ...
(Date:4/17/2014)... new modeling study suggests that fish consumption advisories ... exposure to long-lived contaminants like persistent organic pollutants ... team of researchers including University of Toronto Scarborough ... looks at how different levels of environmental contamination, ... of chemicals in the body influenced exposure in ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Chickens to chili peppers 2Chickens to chili peppers 3Fish consumption advisories fail to cover all types of contaminants 2
... piece to the mounting body of evidence that suggests ... "passive ventilation" significantly increases survival rates, compared to the ... an online edition of Annals of Emergency Medicine, compared ... arrest outside a hospital setting and were resuscitated in ...
... University of Jerusalem have succeeded for the first time ... basic cellular mechanism that enables networks of neurons to ... research may lead to the upgrading of computer algorithms ... as to the development of innovative treatments for auditory ...
... August 11, 2009 Researchers at the Department of ... the effects of formal education on the symptoms of ... diminishes the impact of Alzheimer,s disease on cognition even ... The results are published in the current issue of ...
Cached Biology News:Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Hebrew U. researchers shed light on the brain mechanism responsible for processing of speech 2Formal education lessens the impact of Alzheimer's disease 2
... Oncostatin M (OSM) is a pleiotropic cytokine ... Kaposis sarcoma cells. OSM inhibits the growth ... simulates fibroblast, smooth muscle and Kaposis sarcoma ... and low density lipoprotein receptor expression on ...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... 15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ... is the latanoprost-related isomer containing both ... an inverted (β) hydroxyl group at ... PGF2α isopropyl ester is a potential ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
Biology Products: